Literature DB >> 9920020

Biphasic regulation of the development of murine type II collagen-induced arthritis by interleukin-12: possible involvement of endogenous interleukin-10 and tumor necrosis factor alpha.

T Kasama1, J Yamazaki, R Hanaoka, Y Miwa, Y Hatano, K Kobayashi, M Negishi, H Ide, M Adachi.   

Abstract

OBJECTIVE: To examine the dose-specific effects of interleukin-12 (IL-12) on the evolution of murine type II collagen-induced arthritis (CIA).
METHODS: From day 24 through day 33 following primary immunization, mice received daily intraperitoneal injections of murine recombinant IL-12. Measurements of anticollagen IgG, cytokines, and corticosterone were performed using enzyme-linked immunosorbent assay and radioimmunoassay.
RESULTS: CIA mice injected with a low dose of IL-12 (5 ng/day) exhibited accelerated onset and increased severity of arthritis. In contrast, administration of a high dose of IL-12 (500 ng/day) attenuated arthritic inflammation. The low dose of IL-12 induced tumor necrosis factor alpha (TNFalpha) production, whereas the high dose induced production of both IL-10 and corticosterone and suppression of anticollagen antibody levels. Administration of neutralizing anti-TNFalpha and anti-IL-10 antibodies reversed the dose-specific effects of IL-12.
CONCLUSION: IL-12 is an important immunomodulator during the pathogenesis of CIA. It appears to act by regulating humoral and cellular immune responses, as well as by mediating the expression of immunoregulatory cytokines and glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920020     DOI: 10.1002/1529-0131(199901)42:1<100::AID-ANR13>3.0.CO;2-S

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces foreign-body- and hypersensitivity-type granulomas in mice.

Authors:  H Yamagami; T Matsumoto; N Fujiwara; T Arakawa; K Kaneda; I Yano; K Kobayashi
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 3.  Animal models of rheumatoid arthritis and related inflammation.

Authors:  B Joe; M M Griffiths; E F Remmers; R L Wilder
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

Review 4.  Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

Authors:  Patrizia Murer; Dario Neri
Journal:  N Biotechnol       Date:  2019-04-13       Impact factor: 5.079

5.  A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis.

Authors:  Ryosuke Hanaoka; Tsuyoshi Kasama; Mizuho Muramatsu; Nobuyuki Yajima; Fumitaka Shiozawa; Yusuke Miwa; Masao Negishi; Hirotsugu Ide; Hideyo Miyaoka; Hitoshi Uchida; Mitsuru Adachi
Journal:  Arthritis Res Ther       Date:  2003-01-06       Impact factor: 5.156

6.  The extracellular matrix of eggshell displays anti-inflammatory activities through NF-κB in LPS-triggered human immune cells.

Authors:  Tram T Vuong; Sissel B Rønning; Henri-Pierre Suso; Ralf Schmidt; Kristian Prydz; Marlene Lundström; Anders Moen; Mona E Pedersen
Journal:  J Inflamm Res       Date:  2017-07-04

Review 7.  Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.

Authors:  Franziska Bootz; Dario Neri
Journal:  Drug Discov Today       Date:  2015-10-23       Impact factor: 7.851

8.  Regulation of CD154-induced interleukin-12 production in synovial fluid macrophages.

Authors:  Milja Möttönen; Pia Isomäki; Reijo Luukkainen; Olli Lassila
Journal:  Arthritis Res       Date:  2002-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.